Corporate | 20 April 2012 16:39
|
Cytos Biotechnology AG / Key word(s): AGM/EGM
Schlieren (Zurich), Switzerland, April 20, 2012 – Cytos Biotechnology Ltd (the 'Company') announced that at today's Annual Shareholders' Meeting 2012 the shareholders approved all proposals and hence agreed to the refinancing and in particular to the announced capital increase and the election of the additional members of the board of directors. With this approval the main conditions precedent for the execution of the refinancing are fulfilled and the Company will thus initiate the necessary steps to conclude the capital increase as soon as possible. As the election of Joseph Anderson, Paul Berriman, Paul Brook, Kurt von Emster and Arthur Krieg as additional members of the Board of Directors is only legally valid upon registration of the capital increase in the commercial register, the Board of Directors consists of Dr. Thomas Hecht, president und Jakob Schlapbach, member, up to then. The Annual Shareholders' Meeting took place at the premises of the Company at Schlieren (Zurich), Switzerland. 42 shareholders accepted the invitation. In total 1,804,146 shares were present or represented accounting for 31.32% of the total of 5,760,056 shares issued. As previously announced, existing shareholders have the opportunity to participate in the capital increase by way of a rights offering of up to CHF 5 million. The start and term of the subscription period will be announced in a separate media release. For further information, please contact:
Cytos Biotechnology Ltd
About Cytos Biotechnology Ltd
This foregoing press release may contain forward-looking statements that include words or phrases such as 'are intended for', 'are designed to', or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The Company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of Cytos Biotechnology Ltd. End of Corporate News 20.04.2012 News transmitted by EquityStory AG. The issuer is responsible for the contents of the release. EquityStory publishes regulatory releases, media releases on the capital market and press releases. The EquityStory Group distributes authentic and real-time financial news for over 1’300 listed companies. The Swiss news archive can be found at http://www.equitystory.ch/nachrichten |
| Language: | English | |
| Company: | Cytos Biotechnology AG | |
| Wagistr. 25 | ||
| 8952 Schlieren | ||
| Switzerland | ||
| Phone: | +41 44 733 4747 | |
| Fax: | +41 44 733 4740 | |
| E-mail: | info@cytos.com | |
| Internet: | www.cytos.com | |
| ISIN: | CH0011025217, CH0029060735 | |
| Swiss Security Number: | – | |
| Listed: | Freiverkehr in Berlin, München, Stuttgart; Open Market in Frankfurt; SIX | |
| End of News | EquityStory AG News-Service |
|
|
| 165905 20.04.2012 |